Survival Outcomes in Patients With mRCC Receiving Immune Checkpoint Inhibitor Therapy With or Without Cytoreductive Nephrectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy
Urol. Oncol 2022 Oct 26;[EPub Ahead of Print], EE Gross, M Li, M Yin, et alRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.